The present invention relates to PCSK9 allosteric binding compounds of Formula I: (Formula (I)) and pharmaceutically acceptable salts thereof, wherein X1, X2, Y, R1, R2, RA, RB and n are as defined herein. The present invention also relates to compositions which comprise an allosteric binding compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates, inter alia, to methods for inducing PCSK9 protein degradation in a subject, and methods for treating atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions, comprising administering to a subject an effective amount of a compound or a pharmaceutically acceptable salt of the invention. The invention also provides a means for the in vitro labeling, detection and/or quantification of PCSK9 in biological samples.
本发明涉及Formula I的PCSK9变构结合化合物:(Formula(I))及其药学上可接受的盐,其中X1、X2、Y、R1、R2、RA、RB和n如本文所定义。本发明还涉及包含本发明的变构结合化合物或其药学上可接受的盐以及药学上可接受的载体的组合物。本发明还涉及在受试者中诱导PCSK9蛋白降解的方法,以及治疗动脉粥样硬化、高
胆固醇血症、冠心病、代谢综合征、急性冠状综合征或相关心血管疾病和心脏代谢病症的方法,包括向受试者施用本发明的化合物或药学上可接受的盐的有效量。本发明还提供了在
生物样本中对PCSK9进行体外标记、检测和/或定量的手段。